Skip to main content

Table 4 Baseline data on the patients, continuous variables

From: RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale

 

Double dose of statin

Statin + ezetimibe

p value

 

mean ± sd

n

mean ± sd

n

age

62.6 ± 9.5

56

61.7 ± 11.1

53

0.4949

TC

218.2 ± 27.2

56

212.5 ± 30.1

53

0.3567

TG

161.9 ± 88.3

56

146.7 ± 95.2

53

0.1803

HDL-C

54.7 ± 9.6

56

56.7 ± 15.2

53

0.9734

LDL-C

135.2 ± 22.6

56

130.6 ± 19.2

53

0.5463

non HDL-C

163.6 ± 25.7

56

155.9 ± 26.9

52

0.1133

RLP-C

6.3 ± 3.9

56

6.1 ± 4.8

52

0.4756

apo A1

146.6 ± 16.6

44

144.2 ± 19.2

40

0.3288

apo B

111.4 ± 18.2

44

101.8 ± 16.5

40

0.0152

apo E

4.1 ± 0.9

44

3.8 ± 1.0

40

0.1604

MDA-LDL

157.0 ± 62.0

12

112.6 ± 27.7

9

0.0549

sd-LDL

52.2 ± 17.9

56

46.2 ± 16.0

52

0.0484

Fasting glucose

132.7 ± 32.5

56

141.5 ± 33.1

53

0.1108

Fasting insulin

10.9 ± 7.0

35

13.8 ± 12.5

28

0.5381

ALT

23.6 ± 10.9

56

24.7 ± 12.5

53

0.8318

AST

23.1 ± 12.1

52

23.7 ± 12.2

49

0.8541

γ-GTP

30.2 ± 21.7

53

28.6 ± 26.6

47

0.3248

CK

116.7 ± 58.2

54

122.5 ± 88.3

51

0.9642

Creatinine

0.81 ± 0.28

56

0.79 ± 0.24

51

0.9627

HbA1C

7.15 ± 1.32

56

7.25 ± 0.64

53

0.6294

hs-CRP

1114 ± 1493

56

922 ± 1119

51

0.6025

  1. The data were evaluated using the Wilcoxon test.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X